https://doi.org/10.4081/itjm.2026.2645
The association of neutrophil-to-lymphocyte ratio with bronchiectasis severity assessed by the FACED classification in adults with post-tuberculosis bronchiectasis
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 27 October 2026
The neutrophil-to-lymphocyte ratio (NLR) has emerged as a simple, cost-effective biomarker of systemic inflammation in various respiratory diseases. However, its association with bronchiectasis severity in patients with post-tuberculosis bronchiectasis remains limited. This study aimed to investigate the association between NLR and bronchiectasis severity as assessed by the FACED classification and to identify factors contributing to disease severity in patients with post-tuberculosis bronchiectasis. This retrospective cross-sectional study involved 49 patients with post-tuberculosis bronchiectasis. Bronchiectasis severity was assessed using the FACED score. NLR was calculated from routine complete blood counts. The Mann-Whitney U test compared NLR between mild and moderate severity groups, and factors associated with moderate severity were also analyzed. The median NLR was significantly higher in patients with moderate bronchiectasis compared to those with mild disease (7.16 vs. 3.25, p=0.043), driven primarily by significantly lower lymphocyte percentage in the moderate group (11.20 vs. 22.05, p=0.043). Moderate severity was significantly associated with forced expiratory volume in 1 second <50% predicted (p<0.001), radiological extension involving more than two lobes (p=0.010), and a modified Medical Research Council dyspnea score ≥2 (p=0.049). No significant associations were observed for age, sex, comorbidities, smoking status, or Pseudomonas colonization. Taken together, NLR is significantly elevated in patients with moderate bronchiectasis compared to those with mild disease, primarily reflecting relative reduced lymphocyte percentage in more severe disease. As an easily obtainable, inexpensive biomarker, NLR may serve as a practical tool for initial risk stratification in post-tuberculosis bronchiectasis, particularly in resource-limited settings.
Downloads
Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J 2021;58:2002990. DOI: https://doi.org/10.1183/13993003.02990-2020
Chalmers JD, Mall MA, McShane PJ, et al. A systematic literature review of the clinical and socioeconomic burden of bronchiectasis. Eur Respir Rev 2024;33:240049. DOI: https://doi.org/10.1183/16000617.0049-2024
Chalmers JD, Haworth CS, Flume P, et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. Eur Respir J 2025;66:2501126. DOI: https://doi.org/10.1183/13993003.01126-2025
Martinez-Garcia MA, Guan WJ, de-la-Rosa D, et al. Post-TB bronchiectasis: from pathogenesis to rehabilitation. Int J Tuberc Lung Dis 2023;27:175-81. DOI: https://doi.org/10.5588/ijtld.22.0566
Martínez-García MÁ, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-67. DOI: https://doi.org/10.1183/09031936.00026313
Martinez-García MA, Villa C, Dobarganes Y, et al. RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients. Arch Bronconeumol 2021;57:28-35. DOI: https://doi.org/10.1016/j.arbr.2020.11.010
Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med 2023;11:637-49. DOI: https://doi.org/10.1016/S2213-2600(23)00093-0
Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85. DOI: https://doi.org/10.1164/rccm.201309-1575OC
Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 2021;122:474-88. DOI: https://doi.org/10.4149/BLL_2021_078
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci 2022;23:3636. DOI: https://doi.org/10.3390/ijms23073636
Lan CC, Su WL, Yang MC, et al. Predictive role of neutrophil-percentage-to-albumin, neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios for mortality in patients with COPD: Evidence from NHANES 2011-2018. Respirology 2023;28:1136-46. DOI: https://doi.org/10.1111/resp.14589
Shojaan H, Kalami N, Ghasempour Alamdari M, et al. Diagnostic value of the neutrophil lymphocyte ratio in discrimination between tuberculosis and bacterial community acquired pneumonia: a meta-analysis. J Clin Tuberc Other Mycobact Dis 2023;33:100395. DOI: https://doi.org/10.1016/j.jctube.2023.100395
Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics 2015;70:524-30. DOI: https://doi.org/10.6061/clinics/2015(07)10
Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60:2101499. DOI: https://doi.org/10.1183/13993003.01499-2021
Cheng WC, Chang CL, Sheu CC, et al. Correlating Reiff scores with clinical, functional, and prognostic factors: characterizing noncystic fibrosis bronchiectasis severity: validation from a nationwide multicenter study in Taiwan. Eur J Med Res 2024;29:286. DOI: https://doi.org/10.1183/13993003.congress-2024.PA5111
Man MA, Davidescu L, Motoc NS, et al. Diagnostic value of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in various respiratory diseases: a retrospective analysis. Diagnostics 2021;12:81. DOI: https://doi.org/10.3390/diagnostics12010081
Georgakopoulou VE, Trakas N, Damaskos C, et al. Neutrophils to lymphocyte ratio as a biomarker in bronchiectasis exacerbation: a retrospective study. Cureus 2020;12:e9728. DOI: https://doi.org/10.7759/cureus.9728
Gao Z, Feng Y, Xu J, Liang J. T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. Front Immunol 2022;13:977394. DOI: https://doi.org/10.3389/fimmu.2022.977394
Coban H, Gungen AC. Is there a correlation between new scoring systems and systemic inflammation in stable bronchiectasis? Can Respir J 2017;2017:9874068. DOI: https://doi.org/10.1155/2017/9874068
Kwok WC, Ho JCM, Lam DCL, et al. Baseline neutrophil-to-lymphocyte ratio as a predictor of response to hospitalized bronchiectasis exacerbation risks. Eur Clin Respir J 2024;11:2372901. DOI: https://doi.org/10.1080/20018525.2024.2372901
Martinez-García MÁ, Olveira C, Girón R, et al. Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity. Biomolecules 2022;12:1399. DOI: https://doi.org/10.3390/biom12101399
Ghosh P, Gerhardson I, Dahlen B, Bossios A. Neutrophil-to-lymphocyte ratio in patients with bronchiectasis and its correlation with low-grade inflammation; preliminary results from a single tertiary center. Eur Respir J 2020;56:2049. DOI: https://doi.org/10.1183/13993003.congress-2020.2049
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res 2018;5:e000348. DOI: https://doi.org/10.1136/bmjresp-2018-000348
Ethics Approval
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.